· 4h · on MSN
FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use
· 56m · on MSN
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
· 3h
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Eisai, Biogen and Leqembi
· 1d
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
· 1d
Biogen, Eisai Get FDA Nod for Leqembi IV Maintenance Dosing
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA approved the maintenance dosing of once every four weeks after 18 months of the initiation phase of once every two weeks.
· 1d
FDA Approves Once-Every-Four-Weeks Maintenance Dosing Of LEQEMBI For Early Alzheimer's Disease
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the
Some results have been hidden because they may be inaccessible to you
Show inaccessible results